Comparison of plasma and oral fluid concentrations of mycophenolic acid and its glucuronide metabolite by LC-MS in kidney transplant patients

[1] Pinsky BW(2009)Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression Am J Transplant 9 2597-2606

[2] Takemoto SK(2014)Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update Arch Toxicol 88 1351-1389

[3] Lentine KL(2007)Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients Clin Pharmacokinet 46 13-58

[4] Burroughs TE(2007)Therapeutic drug measurement of mycophenolic acid derivatives in transplant patients Clin Biochem 40 752-764

[5] Schnitzler MA(2011)Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation Transplant Rev 25 78-89

[6] Salvalaggio PR(1995)Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics Clin Chem 40 307-313

[7] Staatz CE(2009)High-performance liquid chromatography-mass spectroscopy/mass spectroscopy method for simultaneous quantification of total or free fraction of mycophenolic acid and its glucuronide metabolites Ther Drug Monit 31 717-726

[8] Tett SE(1995)Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics Clin Chem 41 1011-1017

[9] Staatz CE(2001)Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients Clin Biochem 34 17-22

[10] Tett SE(2012)Liquid chromatography-tandem mass spectrometry method for the quantification of mycophenolic acid and its phenolic glucuronide in saliva and plasma using a standardized saliva collection device J Chromatogr A 1241 52-59

[1] Pinsky BW(2009)Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression Am J Transplant 9 2597-2606

[2] Takemoto SK(2014)Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update Arch Toxicol 88 1351-1389

[3] Lentine KL(2007)Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients Clin Pharmacokinet 46 13-58

[4] Burroughs TE(2007)Therapeutic drug measurement of mycophenolic acid derivatives in transplant patients Clin Biochem 40 752-764

[5] Schnitzler MA(2011)Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation Transplant Rev 25 78-89

[6] Salvalaggio PR(1995)Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics Clin Chem 40 307-313

[7] Staatz CE(2009)High-performance liquid chromatography-mass spectroscopy/mass spectroscopy method for simultaneous quantification of total or free fraction of mycophenolic acid and its glucuronide metabolites Ther Drug Monit 31 717-726

[8] Tett SE(1995)Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics Clin Chem 41 1011-1017

[9] Staatz CE(2001)Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients Clin Biochem 34 17-22

[10] Tett SE(2012)Liquid chromatography-tandem mass spectrometry method for the quantification of mycophenolic acid and its phenolic glucuronide in saliva and plasma using a standardized saliva collection device J Chromatogr A 1241 52-59